UB Paderborn / Katalog / Suche / in CDI

1 – 24 von 24

Sortiert nach

Targeting isocitrate dehydrogenase (IDH) in cancer

Discovery medicine, 2016-05, Vol.21 (117), p.373-380

2016

Volltextzugriff (PDF)

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

British journal of cancer, 2020-11, Vol.123 (10), p.1496-1501

2020

Volltextzugriff (PDF)

The mu opioid receptor: A new target for cancer therapy?

Cancer, 2015-08, Vol.121 (16), p.2681-2688

2015

Volltextzugriff (PDF)

Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers

Radiology, 2017-05, Vol.283 (2), p.314

2017

Volltextzugriff (PDF)

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

Oncotarget, 2014-05, Vol.5 (10), p.3029-3038

2014

Volltextzugriff (PDF)

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

Cancer chemotherapy and pharmacology, 2014-03, Vol.73 (3), p.495-501

2014

Volltextzugriff (PDF)

Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway

Journal of clinical oncology, 2013-03, Vol.31 (9), p.e137-e140

2013

Volltextzugriff (PDF)

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms

Oncotarget, 2014-05, Vol.5 (9), p.2349-2354

2014

Volltextzugriff (PDF)

Multiple gene aberrations and breast cancer: lessons from super-responders

BMC cancer, 2015-05, Vol.15 (1), p.442, Article 442

2015

Volltextzugriff (PDF)

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

Oncoscience, 2016, Vol.3 (5-6), p.164-172

2016

Volltextzugriff (PDF)

Su1015 Transient Severe Hyperbilirubinemia After Hepatic Arterial Infusion of Oxaliplatin in Patients With Liver Metastases

Gastroenterology (New York, N.Y. 1943), 2013-05, Vol.144 (5), p.S-994-S-994

2013

Volltextzugriff (PDF)

Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases

Cancer chemotherapy and pharmacology, 2013-12, Vol.72 (6), p.1265-1271

2013

Volltextzugriff (PDF)

Nanotherapeutic Solutions for Cardiovascular Disease

Methodist DeBakey cardiovascular journal, 2016-09, Vol.12 (3), p.132-133

2016

Volltextzugriff (PDF)

Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical Trials

Journal of oncology practice, 2016-07, Vol.12 (7), p.e784

2016

Volltextzugriff (PDF)

Abstract 1209: Next generation sequencing demonstrates multiple gene amplifications and mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.1209-1209

2013

Volltextzugriff (PDF)

Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.P2-P2-05-03

2015

Volltextzugriff (PDF)

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation

Cancer discovery, 2016-12, Vol.6 (12), p.1352-1365

2016

Volltextzugriff (PDF)

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation

Cancer discovery, 2016-10, Vol.6 (12), p.1352-1365

2016

Volltextzugriff (PDF)

Next-generation sequencing (NGS) in patients with advanced metastatic breast cancer: Identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.1051-1051

2013

Volltextzugriff (PDF)

Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.A212-A212

2013

Volltextzugriff (PDF)

PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2606-2606

2014

Volltextzugriff (PDF)

Abstract 3514: A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the PI3K/AKT/mTOR pathway

Cancer research (Chicago, Ill.), 2013-04, Vol.73 (8_Supplement), p.3514-3514

2013

Volltextzugriff (PDF)

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

Cancer discovery, 2016-12, Vol.6 (12), p.1352

2016

Volltextzugriff (PDF)

Three-Year Survival in Stage IV Non-Small Cell Lung Cancer (NSCLC): The Importance of Metastatic Distribution

Open journal of thoracic surgery, 2013, Vol.3 (2), p.42-46

2013

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(16)
Mit Volltextzugriff
(22)

Publikationsform

Artikel
(24)

Sprache

Englisch
(24)
Japanisch
(1)

Erscheinungsjahr

n.n

Zeitschrift / Serie

Cancer Discovery
(3)
Cancer Research
(3)
Journal Of Clinical Oncology
(3)
Cancer Chemotherapy And Pharmacology
(2)
Oncotarget
(2)
Bmc Cancer
(1)
British Journal Of Cancer
(1)
Cancer
(1)
Discovery Medicine
(1)
Gastroenterology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting isocitrate dehydrogenase (IDH) in cancer

Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials

The mu opioid receptor: A new target for cancer therapy?

Cancer Genomics and Important Oncologic Mutations: A Contemporary Guide for Body Imagers

Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers

Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms

Multiple gene aberrations and breast cancer: lessons from super-responders

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

Su1015 Transient Severe Hyperbilirubinemia After Hepatic Arterial Infusion of Oxaliplatin in Patients With Liver Metastases

Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases

Nanotherapeutic Solutions for Cardiovascular Disease

Innovative Strategies for Decreasing Blood Collection Wait Times for Patients in Early-Phase Cancer Clinical Trials

Abstract 1209: Next generation sequencing demonstrates multiple gene amplifications and mutations in 3 patients with estrogen receptor-positive breast cancer with responses to treatment with combination aromatase and PI3K/AKT/mTOR pathway inhibition

Abstract P2-05-03: Anastrozole and everolimus in hormone receptor-positive metastatic breast cancer: Safety profile, activity and associations of molecular alterations in the PI3K/AKT/mTOR pathway

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation

Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation

Next-generation sequencing (NGS) in patients with advanced metastatic breast cancer: Identification of molecular alterations and analysis of associations with treatment on phase I studies at MD Anderson Cancer Center

Abstract A212: Next generation sequencing (NGS) in 57 patients with advanced or metastatic breast cancer: Identification of unique genomic profiles and correlation with response

PI3K/AKT/mTOR genomic alterations in 94 patients with metastatic breast cancer in the phase I clinic at MD Anderson: Prevalence and association with response

Abstract 3514: A dose-escalation study of anastrozole and everolimus in patients with advanced gynecologic and breast malignancies: tolerance, biological activity, and molecular alterations in the PI3K/AKT/mTOR pathway

Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation

Three-Year Survival in Stage IV Non-Small Cell Lung Cancer (NSCLC): The Importance of Metastatic Distribution

Suchergebnisse filtern